Related Experiment Videos

Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia

Inbal Avisar1, J Gerald Brook, Efrat Wolfovitz

  • 1Bnai Zion Medical Center, Rambam Medical Center and the Technion Faculty of Medicine, Haifa, Israel.

European Journal of Internal Medicine
|April 9, 2008
PubMed

Insights

Atorvastatin monotherapy effectively managed mixed hyperlipidemia in many patients, offering an alternative to statin-fibrate combination therapy. This study suggests atorvastatin is a suitable option for achieving lipid targets.

Area of Science:

  • Cardiology
  • Pharmacology
  • Metabolic Disorders

Background:

  • Mixed hyperlipidemia is a common condition requiring combination therapy for effective lipid management.
  • Current treatments often involve statins and fibric acid derivatives to reach target cholesterol and triglyceride levels.
  • Atorvastatin, an HMG-CoA reductase inhibitor, is known for its efficacy in lowering cholesterol and triglycerides.

Purpose of the Study:

  • To evaluate the efficacy of atorvastatin monotherapy versus combination statin-fibrate therapy in patients with mixed hyperlipidemia.
  • To determine if atorvastatin monotherapy can achieve similar or better lipid profiles compared to existing combination treatments.

Main Methods:

  • A 24-week, prospective, randomized, open-label study involving 27 patients with mixed hyperlipidemia.
  • Patients previously treated with statin-fibrate therapy were switched to 20 mg of atorvastatin daily.
  • Lipid profiles and safety were assessed throughout the study.

Main Results:

  • Atorvastatin monotherapy significantly reduced total cholesterol, LDL-C, and HDL-C compared to statin-fibrate.
  • Triglyceride and glucose levels were significantly elevated with atorvastatin.
  • Target LDL-C and TG levels were achieved in more patients with atorvastatin monotherapy (10/27) than with statin-fibrate (6/27).
  • Atorvastatin was as effective or better than combination therapy in 16 patients.

Conclusions:

  • Atorvastatin monotherapy is an adequate treatment for a significant portion of patients with mixed hyperlipidemia.
  • Consideration of atorvastatin as a primary treatment for mixed hyperlipidemia is recommended.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...